Tuesday, 13 January 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 13 January 2026
News

New GM welcomes drug approval

Posted 13 January 2025 PM

Gilead’s Yeytuo – the first and only twice-yearly pre-exposure prophylaxis (PrEP) option - has been approved by the TGA, providing a vital tool in Australia’s goal to virtually eliminate HIV transmissions by 2030.

While Yeytuo contains lenacapavir - the same active as Gilead’s Sunlenca - it is approved for use as a PrEP to reduce the risk of sexually acquired HIV-1 in adults and adolescents 16 years and older weighing at least 35kg.

To see the whole article, please login

Popular

New Year, new pharma on the PBS
Job moves mark start of 2026
TGA kicks off with first-in-class nod
'No deal' drugs face PBAC review
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home